Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines

• Published in: The Journal of infectious diseases Vol. 225; no. 2; pp. 327 - 331
• Main Authors: Ambrosino, Donna, Han, Htay Htay, Hu, Branda, Liang, Joshua, Clemens, Ralf, Johnson, Marina, Siber, George, Goldblatt, David
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 18.01.2022
• Subjects: Antibodies, Neutralizing; Antibodies, Viral; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; CpG islands; Humans; Immune response; Immunogenicity; Immunogenicity, Vaccine; Major and Brief Reports; Pandemics - prevention & control; SARS-CoV-2 - drug effects; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Spike protein; Trimers; Vaccine Efficacy; Vaccines; Vaccines, Subunit; COVID-19; vaccine; variants of concern; immunogenicity
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/jiab574

Abstract A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines. The antibody-binding responses to the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, were compared with approved vaccines and accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons should be considered as a basis for authorization of vaccines.